# Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

> **NCT07486479** · PHASE3 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 204 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome
- **DRUG:** Venetoclax
- **DRUG:** Azacitidine
- **DRUG:** Idarubicin
- **DRUG:** Cytarabine

## Key facts

- **NCT ID:** NCT07486479
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486479, "Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07486479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*